WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Jennifer Garner, 52, reveals she had no difficulty conceiving her three kids with exThe 49ers are counting on new defensive coordinator Nick Sorensen to get the unit back to dominanceMother's Day: New York's Rikers Island jail gets kidI'm a researcher who studies 100Closing prices for crude oil, gold and other commoditiesCody Bellinger delivers four hits, including a homer, as the Cubs surge past the Pirates 7Korda shoots 66 to keep bid alive for 6th straight LPGA Tour win. She trails Zhang, Sagstom by 4Solar storm creates light show across the world, no serious problems reportedTips to make a house safe and accessible for older adultsCharlie Blackmon's 2
2.5364s , 6516.09375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Investigation news portal